Inicio › Linfoma de Burkitt › Colorado
Ensayos clínicos de Linfoma de Burkitt en Colorado
13 estudios sobre Linfoma de Burkitt buscan participantes en Colorado.
Ciudades en Colorado
Texto oficial del estudio (inglés)
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Children's Hospital Colorado, Aurora
ReclutandoFase 1
Edades de 0 a 18 · Todos los sexos · Actualizado el 13 nov 2026 · NCT06173518A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital Colorado, Aurora
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
ReclutandoFase 2
Edades de 1 a 30 · Todos los sexos · Actualizado el 12 nov 2026 · NCT04546399Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016), Aurora
ReclutandoFase 1/2
6 Months – 25 Years · Todos los sexos · Actualizado el 30 oct 2026 · NCT06395103Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital Colorado, Aurora
ReclutandoEstudio observacional
Edades de 0 a 38 · Todos los sexos · Actualizado el 29 oct 2026 · NCT06131801Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Hospital Colorado, Aurora
ReclutandoFase 2
365 Days · Todos los sexos · Actualizado el 27 oct 2026 · NCT06317662A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital Colorado, Aurora
ReclutandoFase 2
366 Days – 46 Years · Todos los sexos · Actualizado el 27 oct 2026 · NCT06124157Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Colorado Blood Cancer Institute, Denver
ReclutandoFase 1/2
Edades de 13 a 90 · Todos los sexos · Actualizado el 26 oct 2026 · NCT06533579Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- CBCI, Colorado Blood Cancer Institute, Denver
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 oct 2026 · NCT07648264UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
- Children's Hospital Colorado, Aurora
ReclutandoFase 1/2
31 Days – 30 Years · Todos los sexos · Actualizado el 14 sept 2026 · NCT04544592Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Hospital Colorado, Aurora
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
ReclutandoFase 3
365 Days – 25 Years · Todos los sexos · Actualizado el 25 ago 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Colorado Children's Hospital, Denver
ReclutandoFase 2
Edades de 7 a 25 · Todos los sexos · Actualizado el 19 ago 2026 · NCT05082519CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
- Children's Hospital Colorado, Aurora
ReclutandoFase 1
3 Months – 30 Years · Todos los sexos · Actualizado el 28 nov 2025 · NCT06559189The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Children's Hospital Colorado, Aurora
ReclutandoFase 2
Edades de 1 a 25 · Todos los sexos · Actualizado el 4 may 2025 · NCT03509961De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.